Shedding light on prion disease

Prion

Volumn 9, Issue 4, 2015, Pages 244-256

  Glatzel, Markus ^a   Linsenmeier, Luise ^a   Dohler, Frank ^a   Krasemann, Susanne ^a   Puig, Berta ^a   Altmeppen, Hermann C ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

ADAM10; Neurodegeneration; Prion disease; Proteolytic processing; Shedding

Indexed keywords

ADAM10 ENDOPEPTIDASE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GLYCOSYLPHOSPHATIDYLINOSITOL DIACYLGLYCEROL LYASE; ADAM PROTEIN; PRION PROTEIN;

ARTICLE; NEUROTOXICITY; NONHUMAN; PRION DISEASE; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN PROCESSING; STRUCTURAL PROTEOMICS; VIRUS SHEDDING; ANIMAL; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MOUSE;

ADAM PROTEINS; ANIMALS; HUMANS; MICE; MICE, KNOCKOUT; PRION DISEASES; PRPC PROTEINS;

EID: 84954209318     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.1080/19336896.2015.1065371     Document Type: Article

References (121)

1. Riesner D. Biochemistry and structure of PrP(C) and PrP(Sc). Br Med Bull 2003; 66:21–33; PMID:14522846; http://dx.doi.org/10.1093/bmb/66.1.21
2. Biasini E, Turnbaugh JA, Unterberger U, Harris DA. Prion protein at the crossroads of physiology and disease. Trends Neurosci 2012; 35:92-103; PMID:22137337; http://dx.doi.org/10.1016/j.tins.2011.10.002
3. Head MW. Human prion diseases: molecular, cellular and population biology. Neuropathology 2013; 33:221-36; PMID:23331517; http://dx.doi.org/10.1111/neup.12016
4. Imran M, Mahmood S. An overview of animal prion diseases. Virol J 2011; 8:493; PMID:22044871; http://dx.doi.org/10.1186/1743-422X-8-493
5. Prusiner SB. Prions. Proc Natl Acad Sci U S A 1998; 95:13363-83; PMID:9811807; http://dx.doi.org/10.1073/pnas.95.23.13363
6. Supattapone S. Prion protein conversion in vitro. J Mol Med 2004; 82(6):348-56; PMID:15014886
7. Barria MA, Mukherjee A, Gonzalez-Romero D, Morales R, Soto C. De novo generation of infectious prions in vitro produces a new disease phenotype. PLoS Pathog 2009; 5:e1000421; PMID:19436715; http://dx.doi.org/10.1371/journal.ppat.1000421
8. Silva CJ, Vazquez-Fernandez E, Onisko B, Requena JR. Proteinase K and the structure of PrP: the good, the bad and the ugly. Virus Res 2015; PMID:25816779
9. Harris DA, Huber MT, van Dijken P, Shyng SL, Chait BT, Wang R. Processing of a cellular prion protein: identification of N- and C-terminal cleavage sites. Biochemistry 1993; 32:1009-16; PMID:8093841; http://dx.doi.org/10.1021/bi00055a003
10. Stahl N, Borchelt DR, Hsiao K, Prusiner SB. Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 1987; 51:229-40; PMID:2444340; http://dx.doi.org/10.1016/0092-8674(87)90150-4
11. Bremer J, Baumann F, Tiberi C, Wessig C, Fischer H, Schwarz P, Steele AD, Toyka KV, Nave KA, Weis J, et al. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci 2010; 13:310-8; PMID:20098419; http://dx.doi.org/10.1038/nn.2483
12. Westergard L, Turnbaugh JA, Harris DA. A naturally occurring C-terminal fragment of the prion protein (PrP) delays disease and acts as a dominantnegative inhibitor of PrPSc formation. J Biol Chem 2011; 286:44234-42; PMID:22025612; http://dx.doi.org/10.1074/jbc.M111.286195
13. Guillot-Sestier MV, Sunyach C, Druon C, Scarzello S, Checler F. The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. J Biol Chem 2009; 284:35973-86; PMID:19850936; http://dx.doi.org/10.1074/jbc.M109.051086
14. Guillot-Sestier MV, Sunyach C, Ferreira ST, Marzolo MP, Bauer C, Thevenet A, Checler F. alpha-Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid beta (Abeta)-associated cell death. J Biol Chem 2012; 287:5021-32; PMID:22184125; http://dx.doi.org/10.1074/jbc.M111.323626
15. Resenberger UK, Harmeier A, Woerner AC, Goodman JL, Muller V, Krishnan R, Vabulas RM, Kretzschmar HA, Lindquist S, Hartl FU, et al. The cellular prion protein mediates neurotoxic signaling of beta-sheet-rich conformers independent of prion replication. EMBO J 2011; 30:2057-70; PMID:21441896; http://dx.doi.org/10.1038/emboj.2011.86
16. Beland M, Motard J, Barbarin A, Roucou X. PrP(C) homodimerization stimulates the production of PrPC cleaved fragments PrPN1 and PrPC1. J Neurosci 2012; 32:13255-63; PMID:22993441; http://dx.doi.org/10.1523/JNEUROSCI.2236-12.2012
17. Fluharty BR, Biasini E, Stravalaci M, Sclip A, Diomede L, Balducci C, La Vitola P, Messa M, Colombo L, Forloni G, et al. An N-terminal fragment of the prion protein binds to amyloid-beta oligomers and inhibits their neurotoxicity in vivo. J Biol Chem 2013; 288:7857-66; PMID:23362282; http://dx.doi.org/10.1074/jbc.M112.423954
18. Liang J, Kong Q. alpha-Cleavage of cellular prion protein. Prion 2012; 6:453-60; PMID:23052041; http://dx.doi.org/10.4161/pri.22511
19. Altmeppen HC, Puig B, Dohler F, Thurm DK, Falker C, Krasemann S, Glatzel M. Proteolytic processing of the prion protein in health and disease. Am J Neurodegener Dis 2012; 1:15-31; PMID:23383379
20. Altmeppen HC, Prox J, Puig B, Dohler F, Falker C, Krasemann S, Glatzel M. Roles of endoproteolytic alpha-cleavage and shedding of the prion protein in neurodegeneration. FEBS J 2013; 280:4338-47; PMID:23413979; http://dx.doi.org/10.1111/febs.12196
21. Tagliavini F, Prelli F, Porro M, Salmona M, Bugiani O, Frangione B. A soluble form of prion protein in human cerebrospinal fluid: implications for prionrelated encephalopathies. Biochem Biophys Res Commun 1992; 184:1398-404; PMID:1375461; http://dx.doi.org/10.1016/S0006-291X(05)80038-5
22. Perini F, Vidal R, Ghetti B, Tagliavini F, Frangione B, Prelli F. PrP27-30 is a normal soluble prion protein fragment released by human platelets. Biochem Biophys Res Commun 1996; 223:572-7; PMID:8687437; http://dx.doi.org/10.1006/bbrc.1996.0936
23. MacGregor I, Hope J, Barnard G, Kirby L, Drummond O, Pepper D, Hornsey V, Barclay R, Bessos H, Turner M, et al. Application of a time-resolved fluoroimmunoassay for the analysis of normal prion protein in human blood and its components. Vox Sang 1999; 77:88-96; PMID:10516553; http://dx.doi.org/10.1046/j.1423-0410.1999.7720088.x
24. Borchelt DR, Rogers M, Stahl N, Telling G, Prusiner SB. Release of the cellular prion protein from cultured cells after loss of its glycoinositol phospholipid anchor. Glycobiology 1993; 3:319-29; PMID:7691278; http://dx.doi.org/10.1093/glycob/3.4.319
25. Parizek P, Roeckl C, Weber J, Flechsig E, Aguzzi A, Raeber AJ. Similar turnover and shedding of the cellular prion protein in primary lymphoid and neuronal cells. J Biol Chem 2001; 276:44627-32; PMID:11571302; http://dx.doi.org/10.1074/jbc.M107458200
26. Zhao H, Klingeborn M, Simonsson M, Linne T. Proteolytic cleavage and shedding of the bovine prion protein in two cell culture systems. Virus Res 2006; 115:43-55; PMID:16140411; http://dx.doi.org/10.1016/j.virusres.2005.07.004
27. Parkin ET, Watt NT, Turner AJ, Hooper NM. Dual mechanisms for shedding of the cellular prion protein. J Biol Chem 2004; 279:11170-8; PMID:14711812; http://dx.doi.org/10.1074/jbc.M312105200
28. Taylor DR, Parkin ET, Cocklin SL, Ault JR, Ashcroft AE, Turner AJ, Hooper NM. Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein. J Biol Chem 2009;284:22590-600; PMID:19564338; http://dx.doi.org/10.1074/jbc.M109.032599
29. McDonald AJ, Dibble JP, Evans EG, Millhauser GL. A new paradigm for enzymatic control of alpha-cleavage and beta-cleavage of the prion protein. J Biol Chem 2014; 289:803-13; PMID:24247244; http://dx.doi.org/10.1074/jbc.M113.502351
30. Cisse MA, Sunyach C, Lefranc-Jullien S, Postina R, Vincent B, Checler F. The disintegrin ADAM9 indirectly contributes to the physiological processing of cellular prion by modulating ADAM10 activity. J Biol Chem 2005; 280:40624-31; PMID:16236709; http://dx.doi.org/10.1074/jbc.M506069200
31. Tousseyn T, Thathiah A, Jorissen E, Raemaekers T, Konietzko U, Reiss K, Maes E, Snellinx A, Serneels L, Nyabi O, et al. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase. J Biol Chem 2009; 284:11738-47; PMID:19213735; http://dx.doi.org/10.1074/jbc.M805894200
32. Moss ML, Powell G, Miller MA, Edwards L, Qi B, Sang QX, De Strooper B, Tesseur I, Lichtenthaler SF, Taverna M, et al. ADAM9 inhibition increases membrane activity of ADAM10 and controls alpha-secretase processing of amyloid precursor protein. J Biol Chem 2011; 286:40443-51; PMID:21956108; http://dx.doi.org/10.1074/jbc.M111.280495
33. Stahl N, Baldwin MA, Burlingame AL, Prusiner SB. Identification of glycoinositol phospholipid linked and truncated forms of the scrapie prion protein. Biochemistry 1990; 29:8879-84; PMID:1980209; http://dx.doi.org/10.1021/bi00490a001
34. Endres K, Mitteregger G, Kojro E, Kretzschmar H, Fahrenholz F. Influence of ADAM10 on prion protein processing and scrapie infectiosity in vivo. Neurobiol Dis 2009; 36:233-41; PMID:19632330; http://dx.doi.org/10.1016/j.nbd.2009.07.015
35. Hartmann D, de Strooper B, Serneels L, Craessaerts K, Herreman A, Annaert W, Umans L, L€ubke T, Lena Illert A, von Figura K, et al. The disintegrin/metalloprotease ADAM 10 is essential for Notch signalling but not for alpha-secretase activity in fibroblasts. Hum Mol Genet 2002; 11:2615-24; http://dx.doi.org/10.1093/hmg/11.21.2615
36. Jorissen E, Prox J, Bernreuther C, Weber S, Schwanbeck R, Serneels L, Snellinx A, Craessaerts K, Thathiah A, Tesseur I, et al. The disintegrin/metalloproteinase ADAM10 is essential for the establishment of the brain cortex. J Neurosci 2010; 30:4833-44; http://dx.doi.org/10.1523/JNEUROSCI.5221-09.2010
37. Prox J, Bernreuther C, Altmeppen H, Grendel J, Glatzel M, D’Hooge R, Stroobants S, Ahmed T, Balschun D, Willem M, et al. Postnatal disruption of the disintegrin/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic functions. J Neurosci 2013; 33:12915-28, 28a; PMID:23926248; http://dx.doi.org/10.1523/JNEUROSCI.5910-12.2013
38. Altmeppen HC, Prox J, Puig B, Kluth MA, Bernreuther C, Thurm D, Jorissen E, Petrowitz B, Bartsch U, De Strooper B, et al. Lack of a-disintegrin-and-metalloproteinase ADAM10 leads to intracellular accumulation and loss of shedding of the cellular prion protein in vivo. Mol Neurodegener 2011; 6:36; PMID:21619641; http://dx.doi.org/10.1186/1750-1326-6-36
39. Altmeppen HC, Prox J, Krasemann S, Puig B, Kruszewski K, Dohler F, Bernreuther C, Hoxha A, Linsenmeier L, Sikorska B, et al. The sheddase ADAM10 is a potent modulator of prion disease. eLife 2015; 4; PMID:25654651; doi:10.7554/eLife.04260252
40. McNally KL, Ward AE, Priola SA. Cells expressing anchorless prion protein are resistant to scrapie infection. J Virol 2009; 83:4469-75; PMID:19225008; http://dx.doi.org/10.1128/JVI.02412-08
41. Enari M, Flechsig E, Weissmann C. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody. Proc Natl Acad Sci U S A 2001; 98:9295-9; PMID:11470893; http://dx.doi.org/10.1073/pnas.151242598
42. Caughey B, Raymond GJ. The scrapie-associated form of PrP is made from a cell surface precursor that is both protease- and phospholipase-sensitive. J Biol Chem 1991; 266:18217-23; PMID:1680859
43. Meier P, Genoud N, Prinz M, Maissen M, Rulicke T, Zurbriggen A, Raeber AJ, Aguzzi A. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell 2003; 113:49-60; PMID:12679034; http://dx.doi.org/10.1016/S0092-8674(03)00201-0
44. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, LaCasse R, Raymond L, Favara C, Baron G, Priola S, et al. Anchorless prion protein results in infectious amyloid disease without clinical scrapie. Science 2005; 308:1435-9; PMID:15933194; http://dx.doi.org/10.1126/science.1110837
45. Chesebro B, Race B, Meade-White K, Lacasse R, Race R, Klingeborn M, Striebel J, Dorward D, McGovern G, Jeffrey M. Fatal transmissible amyloid encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. PLoS Pathog 2010; 6:e1000800; PMID:20221436; http://dx.doi.org/10.1371/journal.ppat.1000800
46. Stohr J, Watts JC, Legname G, Oehler A, Lemus A, Nguyen HO, Sussman J, Wille H, DeArmond SJ, Prusiner SB, et al. Spontaneous generation of, anchorless prions in transgenic mice. Proc Natl Acad Sci U S A 2011; 108:21223-8; PMID:22160704; http://dx.doi.org/10.1073/pnas.1117827108
47. Büeler HR, Aguzzi A, Sailer A, Greiner RA, Autenried P, Aguet M, Weissmann C. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73:1339-47; PMID:8100741; http://dx.doi.org/10.1016/0092-8674(93)90360-3
48. Brandner S, Isenmann S, Raeber A, Fischer M, Sailer A, Kobayashi Y, Marino S, Weissmann C, Aguzzi A. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 1996; 379:339-43; PMID:8552188; http://dx.doi.org/10.1038/379339a0
49. Mallucci G, Dickinson A, Linehan J, Klohn PC, Brandner S, Collinge J. Depleting neuronal PrP in bprion infection prevents disease and reverses spongiosis. Science 2003; 302:871-4; PMID:14593181; http://dx.doi.org/10.1126/science.1090187
50. Resenberger UK, Winklhofer KF, Tatzelt J. Neuroprotective and neurotoxic signaling by the prion protein. Top Curr Chem 2011; 305:101-19; PMID:21598098; http://dx.doi.org/10.1007/128_2011_160
51. Sandberg MK, Al-Doujaily H, Sharps B, Clarke AR, Collinge J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 2011; 470:540-2; PMID:21350487; http://dx.doi.org/10.1038/nature09768
52. Radford HE, Mallucci GR. The role of GPIanchored PrP C in mediating the neurotoxic effect of scrapie prions in neurons. Curr Issues Mol Biol 2010; 12:119-27; PMID:19767655
53. Puig B, Altmeppen H, Glatzel M. The GPI-anchoring of PrP: Implications in sorting and pathogenesis. Prion 2014; 8:11-8; PMID:24509692
54. Priola SA, McNally KL. The role of the prion protein membrane anchor in prion infection. Prion 2009; 3:134-8; PMID:19786843; http://dx.doi.org/10.4161/pri.3.3.9771
55. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457:1128-32; PMID:19242475; http://dx.doi.org/10.1038/nature07761
56. Turnbaugh JA, Unterberger U, Saa P, Massignan T, Fluharty BR, Bowman FP, Miller MB, Supattapone S, Biasini E, Harris DA. The N-terminal, polybasic region of PrP(C) dictates the efficiency of prion propagation by binding to PrP(Sc). J Neurosci 2012; 32:8817-30; PMID:22745483; http://dx.doi.org/10.1523/JNEUROSCI.1103-12.2012
57. Dohler F, Sepulveda-Falla D, Krasemann S, Altmeppen H, Schluter H, Hildebrand D, Zerr I, Matschke J, Glatzel M. High molecular mass assemblies of amyloid-beta oligomers bind prion protein in patients with Alzheimer’s disease. Brain 2014; 137:873-86; PMID:24519981; http://dx.doi.org/10.1093/brain/awt375
58. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 2012; 15:1227-35; PMID:22820466; http://dx.doi.org/10.1038/nn.3178
59. Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesne SE. The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer’s disease. J Neurosci 2012; 32:16857-71a; PMID:23175838; http://dx.doi.org/10.1523/JNEUROSCI.1858-12.2012
60. Mouillet-Richard S, Ermonval M, Chebassier C, Laplanche JL, Lehmann S, Launay JM, Kellermann O. Signal transduction through prion protein. Science 2000; 289:1925-8; PMID:10988071; http://dx.doi.org/10.1126/science.289.5486.1925
61. Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem 2005; 280:17294-300; PMID:15722360; http://dx.doi.org/10.1074/jbc.M500997200
62. Kagan BL. Membrane pores in the pathogenesis of neurodegenerative disease. Prog Mol Biol Transl Sci 2012; 107:295-325; PMID:22482454; http://dx.doi.org/10.1016/B978-0-12-385883-2.00001-1
63. Solomon IH, Biasini E, Harris DA. Ion channels induced by the prion protein: mediators of neurotoxicity. Prion 2012; 6:40-5; PMID:22453177; http://dx.doi.org/10.4161/pri.6.1.18627
64. Sonati T, Reimann RR, Falsig J, Baral PK, O’Connor T, Hornemann S, Yaganoglu S, Li B, Herrmann US, Wieland B, et al. The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein. Nature 2013; PMID:23903654
65. Goold R, McKinnon C, Rabbanian S, Collinge J, Schiavo G, Tabrizi SJ. Alternative fates of newly formed PrPSc upon prion conversion on the plasma membrane. J Cell Sci 2013; 126:3552-62; PMID:23813960; http://dx.doi.org/10.1242/jcs.120477
66. Goold R, Rabbanian S, Sutton L, Andre R, Arora P, Moonga J, Clarke AR, Schiavo G, Jat P, Collinge J, et al. Rapid cell-surface prion protein conversion revealed using a novel cell system. Nat Commun 2011; 2:281; PMID:21505437; http://dx.doi.org/10.1038/ncomms1282
67. Fischer M, Rülicke T, Raeber A, Sailer A, Moser M, Oesch B, Brandner S, Aguzzi A, Weissmann C. Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO J 1996; 15:1255-64; PMID:8635458
68. Taraboulos A, Scott M, Semenov A, Avrahami D, Laszlo L, Prusiner SB. Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 1995; 129:121-32; PMID:7698979; http://dx.doi.org/10.1083/jcb.129.1.121
69. Yuan J, Zhan YA, Abskharon R, Xiao X, Martinez MC, Zhou X, Kneale G, Mikol J, Lehmann S, Surewicz WK, et al. Recombinant human prion protein inhibits prion propagation in vitro. Sci Rep 2013;3:2911; PMID:24105336
70. Marella M, Lehmann S, Grassi J, Chabry J. Filipin prevents pathological prion protein accumulation by reducing endocytosis and inducing cellular PrP release. J Biol Chem 2002; 277:25457-64; PMID:11994310; http://dx.doi.org/10.1074/jbc.M203248200
71. Kim JI, Surewicz K, Gambetti P, Surewicz WK. The role of glycophosphatidylinositol anchor in the amplification of the scrapie isoform of prion protein in vitro. FEBS Lett 2009; 583:3671-5; PMID:19854187; http://dx.doi.org/10.1016/j.febslet.2009.10.049
72. Nonno R, Di Bari MA, Cardone F, Vaccari G, Fazzi P, Dell’Omo G, Cartoni C, Ingrosso L, Boyle A, Galeno R, et al. Efficient transmission and characterization of Creutzfeldt-Jakob disease strains in bank voles. PLoS Pathog 2006; 2:e12; PMID:16518470; http://dx.doi.org/10.1371/journal.ppat.0020012
73. Di Bari MA, Nonno R, Castilla J, D’Agostino C, Pirisinu L, Riccardi G, Conte M, Richt J, Kunkle R, Langeveld J, et al. Chronic wasting disease in bank voles: characterisation of the shortest incubation time model for prion diseases. PLoS Pathog 2013; 9:e1003219; PMID:23505374; http://dx.doi.org/10.1371/journal.ppat.1003219
74. Watts JC, Giles K, Patel S, Oehler A, DeArmond SJ, Prusiner SB. Evidence that bank vole PrP is a universal acceptor for prions. PLoS Pathog 2014; 10: e1003990; PMID:24699458; http://dx.doi.org/10.1371/journal.ppat.1003990
75. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009; 64:783-90; PMID:20064386; http://dx.doi.org/10.1016/j.neuron.2009.12.016
76. Costanzo M, Zurzolo C. The cell biology of prisonlike spread of protein aggregates: mechanisms and implication in neurodegeneration. Biochem J 2013; 452:17; PMID:23614720; http://dx.doi.org/10.1042/BJ20130484
77. Walker LC, Jucker M. Neurodegenerative Diseases: Expanding the Prion Concept. Annu Rev Neurosci 2015; PMID:25840008
78. Glatzel M, Aguzzi A. PrP(C) expression in the peripheral nervous system is a determinant of prion neuroinvasion. J Gen Virol 2000; 81:2813-21; PMID:11038396
79. Glatzel M, Heppner FL, Albers KM, Aguzzi A. Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron 2001; 31:25-34; PMID:11498048; http://dx.doi.org/10.1016/S0896-6273(01)00331-2
80. Gousset K, Zurzolo C. Tunnelling nanotubes: a highway for prion spreading? Prion 2009; 3:94-8;PMID:19471116; http://dx.doi.org/10.4161/pri.3.2.8917
81. Leblanc P, Alais S, Porto-Carreiro I, Lehmann S, Grassi J, Raposo G, Darlix JL. Retrovirus infection strongly enhances scrapie infectivity release in cell culture. Embo J 2006; 25:2674-85; PMID:16724107; http://dx.doi.org/10.1038/sj.emboj.7601162
82. Krasemann S, Neumann M, Luepke JP, Grashorn J, Wurr S, Stocking C, Glatzel M. Persistent retroviral infection with MoMuLV influences neuropathological signature and phenotype of prion disease. Acta Neuropathol 2012; 124:111-26; PMID:22271154; http://dx.doi.org/10.1007/s00401-012-0944-1
83. Alais S, Simoes S, Baas D, Lehmann S, Raposo G, Darlix JL, Leblanc P. Mouse neuroblastoma cells release prion infectivity associated with exosomal vesicles. Biol Cell 2008; 100:603-15; PMID:18422484; http://dx.doi.org/10.1042/BC20080025
84. Coleman BM, Hill AF. Extracellular vesicles -Their role in the packaging and spread of misfolded proteins associated with neurodegenerative diseases. Semin Cell Dev Biol 2015; PMID:25704308
85. Shearin H, Bessen RA. Axonal and transynaptic spread of prions. J Virol 2014; 88(15):8640-55; PMID:24850738
86. Klingeborn M, Race B, Meade-White KD, Rosenke R, Striebel JF, Chesebro B. Crucial role for prion protein membrane anchoring in the neuroinvasion and neural spread of prion infection. J Virol 2011; 85:1484-94; PMID:21123371; http://dx.doi.org/10.1128/JVI.02167-10
87. Rangel A, Race B, Klingeborn M, Striebel J, Chesebro B. Unusual cerebral vascular prion protein amyloid distribution in scrapie-infected transgenic mice expressing anchorless prion protein. Acta Neuropathol Commun 2013; 1:25; PMID:24252347; http://dx.doi.org/10.1186/2051-5960-1-25
88. Rangel A, Race B, Phillips K, Striebel J, Kurtz N, Chesebro B. Distinct patterns of spread of prion infection in brains of mice expressing anchorless or anchored forms of prion protein. Acta Neuropathol Commun 2014; 2:8; PMID:24447368; http://dx.doi.org/10.1186/2051-5960-2-8
89. Trifilo MJ, Yajima T, Gu Y, Dalton N, Peterson KL, Race RE, Meade-White K, Portis JL, Masliah E, Knowlton KU, et al. Prion-induced amyloid heart disease with high blood infectivity in transgenic mice. Science 2006; 313:94-7; PMID:16825571; http://dx.doi.org/10.1126/science.1128635
90. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216:136-44; PMID:6801762; http://dx.doi.org/10.1126/science.6801762
91. Castilla J, Saa P, Hetz C, Soto C. In vitro generation of infectious scrapie prions. Cell 2005; 121:195-206; PMID:15851027; http://dx.doi.org/10.1016/j.cell.2005.02.011
92. Weber P, Giese A, Piening N, Mitteregger G, Thomzig A, Beekes M, Kretzschmar HA. Cell-free formation of misfolded prion protein with authentic prion infectivity. Proc Natl Acad Sci U S A 2006; 103:15818-23; PMID:17030802; http://dx.doi.org/10.1073/pnas.0605608103
93. Deleault NR, Harris BT, Rees JR, Supattapone S. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci U S A 2007; 104:9741-6; PMID:17535913; http://dx.doi.org/10.1073/pnas.0702662104
94. Caughey B, Baron GS. Prions and their partners in crime. Nature 2006; 443:803-10; PMID:17051207;http://dx.doi.org/10.1038/nature05294
95. Deleault NR, Walsh DJ, Piro JR, Wang F, Wang X, Ma J, Rees JR, Supattapone S. Cofactor molecules maintain infectious conformation and restrict strain properties in purified prions. Proc Natl Acad Sci U S A 2012; 109:E1938-46; PMID:22711839; http://dx.doi.org/10.1073/pnas.1206999109
96. Supattapone S. Elucidating the role of cofactors in mammalian prion propagation. Prion 2014; 8:100-5; PMID:24365977; http://dx.doi.org/10.4161/pri.27501
97. Wang F, Wang X, Yuan CG, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 2010; 327:1132-5; PMID:20110469; http://dx.doi.org/10.1126/science.1183748
98. Lasmezas CI, Deslys JP, Robain O, Jaegly A, Beringue V, Peyrin JM, Fournier JG, Hauw JJ, Rossier J, Dormont D. Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein. Science 1997; 275:402-5; PMID:8994041; http://dx.doi.org/10.1126/science.275.5298.402
99. Shaked GM, Fridlander G, Meiner Z, Taraboulos A, Gabizon R. Protease-resistant and detergent-insoluble prion protein is not necessarily associated with prion infectivity. J Biol Chem 1999; 274:17981-6; PMID:10364247; http://dx.doi.org/10.1074/jbc.274.25.17981
100. Barron RM, Campbell SL, King D, Bellon A, Chapman KE, Williamson RA, Manson JC. High titers of transmissible spongiform encephalopathy infectivity associated with extremely low levels of PrPSc in vivo. J Biol Chem 2007; 282:35878-86; PMID:17923484; http://dx.doi.org/10.1074/jbc.M704329200
101. Piccardo P, Manson JC, King D, Ghetti B, Barron RM. Accumulation of prion protein in the brain that is not associated with transmissible disease. Proc Natl Acad Sci U S A 2007; 104:4712-7; PMID:17360589; http://dx.doi.org/10.1073/pnas.0609241104
102. Klingeborn M, Race B, Meade-White KD, Chesebro B. Lower specific infectivity of protease-resistant prion protein generated in cell-free reactions. Proc Natl Acad Sci U S A 2011; 108:E1244-53; PMID:22065744; http://dx.doi.org/10.1073/pnas.1111255108
103. Lewis V, Haigh CL, Masters CL, Hill AF, Lawson VA, Collins SJ. Prion subcellular fractionation reveals infectivity spectrum, with a high titre-low PrPres level disparity. Mol Neurodegener 2012; 7:18; PMID:22534096; http://dx.doi.org/10.1186/1750-1326-7-18
104. Krasemann S, Neumann M, Szalay B, Stocking C, Glatzel M. Protease-sensitive prion species in neoplastic spleens of prion-infected mice with uncoupling of PrP(Sc) and prion infectivity. J Gen Virol 2013; 94:453-63; PMID:23136363; http://dx.doi.org/10.1099/vir.0.045922-0
105. Silveira JR, Raymond GJ, Hughson AG, Race RE, Sim VL, Hayes SF, Caughey B. The most infectious prion protein particles. Nature 2005; 437:257-61; PMID:16148934; http://dx.doi.org/10.1038/nature03989
106. Race B, Phillips K, Meade-White K, Striebel J, Chesebro B. Increased infectivity of anchorless mouse scrapie prions in transgenic mice overexpressing human prion protein. J Virol 2015
107. Stahl N, Borchelt DR, Prusiner SB. Differential release of cellular and scrapie prion proteins from cellular membranes by phosphatidylinositol-specific phospholipase C. Biochemistry 1990; 29:5405-12; PMID:1974460; http://dx.doi.org/10.1021/bi00474a028
108. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, Mansuy IM, Aguzzi A. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med 2010; 2:306-14; PMID:20665634; http://dx.doi.org/10.1002/emmm.201000082
109. Nieznanski K, Choi JK, Chen S, Surewicz K, Surewicz WK. Soluble Prion Protein Inhibits Amyloidbeta (Abeta) Fibrillization and Toxicity. J Biol Chem 2012; 287:33104-8; PMID:22915585; http://dx.doi.org/10.1074/jbc.C112.400614
110. Younan ND, Sarell CJ, Davies P, Brown DR, Viles JH. The cellular prion protein traps Alzheimer’s Abeta in an oligomeric form and disassembles amyloid fibers. FASEB J 2013; 27:1847-58; PMID:23335053; http://dx.doi.org/10.1096/fj.12-222588
111. Kanaani J, Prusiner SB, Diacovo J, Baekkeskov S, Legname G. Recombinant prion protein induces rapid polarization and development of synapses in embryonic rat hippocampal neurons in vitro. J Neurochem 2005; 95:1373-86; PMID:16313516; http://dx.doi.org/10.1111/j.1471-4159.2005.03469.x
112. Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, Lingappa VR. A transmembrane form of the prion protein in neurodegenerative disease. Science 1998; 279:827-34; PMID:9452375; http://dx.doi.org/10.1126/science.279.5352.827
113. Emerman AB, Zhang ZR, Chakrabarti O, Hegde RS. Compartment-restricted biotinylation reveals novel features of prion protein metabolism in vivo. Mol Biol Cell 2010; 21:4325-37; PMID:20980618; http://dx.doi.org/10.1091/mbc.E10-09-0742
114. Weber S, Saftig P. Ectodomain shedding and ADAMs in development. Development 2012; 139:3693-709; PMID:22991436; http://dx.doi.org/10.1242/dev.076398
115. Janes PW, Saha N, Barton WA, Kolev MV, Wimmer-Kleikamp SH, Nievergall E, Blobel CP, Himanen JP, Lackmann M, Nikolov DB. Adam meets Eph: an ADAM substrate recognition module acts as a molecular switch for ephrin cleavage in trans. Cell 2005; 123:291-304; PMID:16239146;http://dx.doi.org/10.1016/j.cell.2005.08.014
116. Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D, Saftig P. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. Embo J 2005; 24:742-52; PMID:15692570; http://dx.doi.org/10.1038/sj.emboj.7600548
117. Musardo S, Marcello E, Gardoni F, Di Luca M. ADAM10 in synaptic physiology and pathology. Neurodegener Dis 2014; 13:72-4; PMID:24008925; http://dx.doi.org/10.1159/000354233
118. Suzuki K, Hayashi Y, Nakahara S, Kumazaki H, Prox J, Horiuchi K, Zeng M, Tanimura S, Nishiyama Y, Osawa S, et al. Activity-dependent proteolytic cleavage of neuroligin-1. Neuron 2012; 76:410-22; PMID:23083742; http://dx.doi.org/10.1016/j.neuron.2012.10.003
119. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 2010; 29:3020-32; PMID:20676056; http://dx.doi.org/10.1038/emboj.2010.167
120. Aguzzi A, Baumann F, Bremer J. The prion’s elusive reason for being. Annu Rev Neurosci 2008; 31:439-77; PMID:18558863; http://dx.doi.org/10.1146/annurev.neuro.31.060407.125620
121. Linden R, Martins VR, Prado MA, Cammarota M, Izquierdo I, Brentani RR. Physiology of the prion protein. Physiol Rev 2008; 88:673-728; PMID:18391177; http://dx.doi.org/10.1152/physrev.00007.2007